Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs
- SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, is pleased to announce the appointment of Dr. Mark L. Rubinstein as its new Head of Medical Affairs. Dr. Rubinstein brings more than two decades of experience in clinical medicine, scientific research, and medical affairs leadership, with a strong focus on preventative medicine and nicotine cessation.
- 10/01/2024
|
Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors
- Richard Stewart reassumes role of Chief Executive Officer Thomas King appointed Executive Chairman of the Board of Directors SEATTLE and VANCOUVER, British Columbia, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Mr. Richard (Rick) Stewart, Achieve's co-founder and current Executive Chairman, will reassume the role of Chief Executive Officer.
- 08/26/2024
|
Achieve Life Sciences, Inc. (ACHV) Q2 2024 Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Nicole Jones - IR John Bencich - CEO Cindy Jacobs - President and Chief Medical Officer Jerry Wan - Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Justin Walsh - JonesTrading John Vandermosten - Zacks Ilya Zubkov - Freedom Broker Thomas Flaten - Lake Street Capital Operator Greetings, and welcome to the Achieve Life Sciences Second Quarter 2024 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
- 08/14/2024
|
Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
- Company to host conference call at 4:30 PM EDT today, Tuesday, August 13, 2024 Company to host conference call at 4:30 PM EDT today, Tuesday, August 13, 2024
- 08/13/2024
|
Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence
- Designation is based on results from the Phase 2 ORCA-V1 trial that showed treatment with cytisinicline more than doubled the odds of quitting e-cigarettes compared with placebo Designation is based on results from the Phase 2 ORCA-V1 trial that showed treatment with cytisinicline more than doubled the odds of quitting e-cigarettes compared with placebo
- 07/31/2024
|
Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
- SEATTLE and VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a $20 million debt refinancing agreement with Silicon Valley Bank (SVB), a division of First-Citizens Bank. The new loan agreement refinances the existing debt facility with SVB and SVB Capital and extends the maturity date from August 1, 2024 to December 1, 2027.
- 07/29/2024
|
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024
- SEATTLE and VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2024 financial results and provide an update on the cytisinicline development program on Tuesday, August 13, 2024, at 4:30 PM EDT.
- 07/25/2024
|
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
- SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be attending the JonesHealthcare Seaside Summit 2024 being held July 14-16, 2024, in Encinitas, CA.
- 07/09/2024
|
Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement
- Achieve Life Sciences, Inc. initiated an open-label ORCA-OL trial using cytisinicline for smoking cessation; the Efficacy of the drug already established in several prior studies. Alignment with FDA that successful completion of ORCA-OL trial is necessary for NDA filing of cytisinicline in the 1st half of 2025. The global smoking cessation product market is estimated to reach $69.8 billion by the end of 2034.
- 07/01/2024
|
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
- SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced data from the Phase 2 ORCA-V1 vaping cessation trial will be presented today, Friday, May 17, 2024, at the Society of General Internal Medicine (SGIM) Annual Meeting being held in Boston, MA.
- 05/17/2024
|
Achieve Life Sciences, Inc. (ACHV) Q1 2024 Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jerry Wan - Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Michael Higgins - Ladenburg Thalmann John Vandermosten - Zacks Ilya Zubkov - Freedom Broker Operator Greetings. Welcome to Achieve Life Sciences' First Quarter 2024 Earnings Conference Call and Webcast.
- 05/09/2024
|
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024
- 05/09/2024
|
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
- Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo
- 05/06/2024
|
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
- SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT.
- 04/25/2024
|
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
- Achieve Life Sciences is working to commercialize the smoking cessation drug Cytisinicline, which has shown promising results in clinical trials. The drug has a superior safety profile compared to existing treatment options and has the potential to address a large market. The company is expected to be sold to a larger entity in 2025, with potential returns of 4-9x for investors.
- 04/04/2024
|
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
- Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
- 03/28/2024
|
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
- Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024
- 03/28/2024
|
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
- SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences.
- 03/06/2024
|
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
- Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025 Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025
- 02/29/2024
|
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
- $60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants
- 02/29/2024
|
Why Is Achieve Life Sciences (ACHV) Stock Down 25% Today?
- Achieve Life Sciences (NASDAQ: ACHV ) stock is dropping on Tuesday after the company provided an update on its New Drug Application (NDA) for cytisinicline. A meeting with the Food and Drug Administration (FDA) saw the agency request additional data concerning cytisinicline before it will approve its NDA.
- 12/12/2023
|
Achieve Life Sciences shares drop as analysts see delayed launch of smoking-cessation treatment
- Achieve Life Sciences Inc. shares ACHV, -1.09% dropped 25% premarket on Tuesday as analysts forecasted delays in the launch of the company's smoking cessation treatment cytisinicline. In a recent meeting with the U.S. Food and Drug Administration, the agency said it would need longer-term data beyond 12 weeks to assess potential safety risks of cytisinicline, given that the regulator views smoking cessation drugs as products for chronic, intermittent use, Achieve Life Sciences said in a regulatory filing Monday.
- 12/12/2023
|
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
- SEATTLE and VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences.
- 12/11/2023
|
Achieve Life Sciences, Inc. (ACHV) Q3 2023 Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Nicole Jones - IR John Bencich - CEO Jerry Wan - Principal Accounting Officer Cindy Jacobs - President and CMO Conference Call Participants Thomas Flaten - Lake Street Michael Higgins - Ladenburg Thalmann John Vandermosten - Saks Operator Greetings. Welcome to Achieve Life Sciences Third Quarter Earnings Conference Call and Webcast.
- 11/09/2023
|
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023
- SEATTLE and VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its third quarter 2023 financial results and provide an update on the cytisinicline development program on Thursday, November 9, 2023 at 4:30 PM EST.
- 10/26/2023
|
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
- SEATTLE and VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that management will be participating at two upcoming investor conferences.
- 10/03/2023
|
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
- SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Phase 2 ORCA-V1 trial results will be presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting, being held in London September 11–13, 2023.
- 09/11/2023
|
Achieve Life Sciences, Inc. (ACHV) Q2 2023 Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q2 2023 Earnings Conference Call August 15, 2023 8:30 AM ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Jerry Wan - Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Francois Brisebois - Oppenheimer Farhana Sakloth - Ladenburg Thalmann Laura Suriel - Alliance Resource Partners John Vandermosten - Zacks Research Operator Greetings. Welcome to the Achieve Life Sciences Second Quarter 2023 Earnings Conference Call and Webcast.
- 08/15/2023
|
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
- Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Highlights Publication of Phase 3 ORCA-2 trial results in the Journal of the American Medical Association (JAMA) Reported statistically significant smoking cessation benefit for cytisinicline in the confirmatory Phase 3 ORCA-3 trial Announced Phase 2 ORCA-V1 trial results showing statistically significant vaping cessation benefit with cytisinicline treatment Closed equity financing with gross proceeds of approximately $16.5 million, prior to deducting placement agent commissions and estimated offering expenses Refinanced outstanding loan with Silicon Valley Bank (SVB) "We've had a very exciting and eventful first half of 2023, with two additional clinical trials reading out with positive results for cytisinicline in both smoking and vaping cessation, and the recent publication of the completed Phase 3 ORCA-2 trial in the highly prestigious Journal of the American Medical Association,” commented John Bencich, CEO of Achieve.
- 08/14/2023
|
Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
- SEATTLE and VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2023 financial results on Monday, August 14, 2023, and host a conference call and webcast on Tuesday, August 15, 2023, at 8:30 AM EDT.
- 08/01/2023
|
Achieve: Exciting Smoking Cessation Drug Approval Could Come Soon
- Efficacy: Phase 3 ORCA-3 trial showed significant efficacy of cytisinicline in smoking cessation, reinforcing data from ORCA-2. Safety: Cytisinicline exhibited no serious treatment-related adverse events, implying safe long-term usage.
- 05/28/2023
|
Achieve Life Sciences says confirmatory late-stage trial of its treatment for quitting smoking achieved positive results
- Achieve Life Sciences Inc. ACHV, +12.88% said Tuesday a second confirmatory late-stage trial of its cytisinicline for quitting smoking and nicotine dependence achieved positive results, showing a statistically significant benefit compared to placebo. The Phase 3 trial involved 792 adult smokers at 20 trial sites in the U.S. who were dosed 3 times daily with 3mg of cytisinicline for a period of six weeks or 12 weeks.
- 05/23/2023
|
Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
- SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2023 financial results and provide an update on the cytisinicline development program on Tuesday, May 9, 2023 at 4:30 PM EDT.
- 04/26/2023
|
Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs
- Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs.
- 04/25/2023
|
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
- SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2023 Conference being held at the Seattle Convention Center April 25-26, 2023.
- 04/14/2023
|
Achieve Life Sciences, Inc. (ACHV) Q4 2022 Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jerry Wan - Principal Accounting Officer Jaime Xinos - Executive Vice President, Commercial Conference Call Participants Thomas Flaten - Lake Street Capital Michael Higgins - Ladenburg Thalmann Francois Brisebois - Oppenheimer Operator Hello and welcome to the Achieve Life Sciences Fourth Quarter 2022 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
- 03/16/2023
|
Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug
- ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement in quit rates and robust safety profile. Phase 3 ORCA-3 registration trial is ongoing, and we expect the data readout in 2Q 2023; we expect the results to be positive.
- 01/28/2023
|
Achieve Life Sciences, Inc. (ACHV) Q3 2022 Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Nicole Jones - Investor Relations-CG Capital John Bencich - Chief Executive Officer Jerry Wan - Principal Accounting Officer Cindy Jacobs - President & Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital François Brisebois - Oppenheimer Michael Higgins - Ladenburg Thalmann John Vandermosten - Zacks Jim Molloy - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to Achieve Life Sciences Third Quarter 2022 Earnings Conference Call. All lines have been placed on a listen-only mode.
- 11/14/2022
|
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2022 Results - Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer John Bencich - Chief Executive Officer Conference Call Participants Michael Higgins - Ladenburg Thalmann François Brisebois - Oppenheimer John Vandermosten - Zacks Vernon Bernardino - H.C. Wainwright Jim Molloy - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to the Achieve Life Science Second Quarter 2022 Earnings Conference Call.
- 08/11/2022
|
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022
- SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program on Thursday, August 11, 2022, at 4:30 PM EDT.
- 07/28/2022
|
Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
- SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the Spring Into Action Best Ideas Virtual Investor Conference. The conference is taking place virtually from May 16 - 20, 2022. Details for access to the presentation are as follows:
- 05/13/2022
|
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Bencich - CEO & Director Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Michael Higgins - Ladenburg Thalmann & Co. John Vandermosten - Zacks Small-Cap Research Operator Good day, and thank you for standing by. Welcome to the Achieve Life Sciences First Quarter 2022 Earnings Conference Call.
- 05/12/2022
|
Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation
- Achieve Life Sciences Inc (NASDAQ: ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers. The 6- and 12-week cytisinicline treatments demonstrated significantly better.
- 04/27/2022
|
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022
- SEATTLE and VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its first quarter financial results and provide an update on the cytisinicline development program on Thursday, May 12, 2022, at 4:30 PM EDT. To access the webcast, please use the following link 1Q22 Earnings Webcast . Alternatively, you may access the live conference call by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 3887417. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days.
- 04/21/2022
|
Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug
- We are initiating ACHV with a buy rating and a target price of USD 70.
- 04/04/2022
|
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript
- Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript
- 03/10/2022
|
Achieve Life Sciences Announces Participation in March Investor Conferences
- SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in the Oppenheimer 32nd Annual Virtual Healthcare Conference and the Maxim 2022 Virtual Growth Conference.
- 03/08/2022
|
Achieve Life Sciences Announces Participation in February Investor Conferences
- SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in the Winter Wonderland Best Ideas Virtual Investor Conference and Aegis Virtual Conference during February 2022.
- 02/02/2022
|
Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation
- Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cytisinicline dosed three times daily compared to placebo in 750 adult smokers.
- 01/25/2022
|
Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference
- SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The conference is taking place virtually from January 10 - 13, 2022. Details for access to the presentation are as follows:
- 01/06/2022
|
Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program
- Achieve Life Sciences Inc (NASDAQ: ACHV) has entered into a $25 million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program.
- 12/22/2021
|
Achieve Life Sciences Announces Participation in November Investor Conferences
- SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that its management team will hold one-on-one investor meetings at the Alliance Global Partners' (A.G.P.) Biotech & Specialty Pharma Conference and the Torrey Hills Capital Emerging Growth Conference during November 2021. Details are as follows:
- 11/04/2021
|
Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation
- The FDA has signed off Achieve Life Sciences Inc's (NASDAQ: ACHV) Investigational New Drug (IND) application to investigate cytisinicline as a cessation treatment for nicotine e-cigarette users. In addition to the ongoing Phase 3 program for cytisinicline treatment in combustible cigarette cessation, the Company expects to initiate the ORCA-V1 e-cigarette and vape cessation trial in Q2 of 2022.
- 11/02/2021
|
Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021
- Seattle, WA/ Vancouver, BC , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third-quarter 2021 financial results and provide an update on the cytisinicline development program on Tuesday, November 9, 2021, at 4:30 PM EST.
- 10/26/2021
|
Achieve Life Sciences to Participate in Upcoming Investor Conferences
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will participate in two upcoming investor conferences. Mr. Bencich will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 21st at 3:45PM ET.
- 09/15/2021
|
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
- SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming Society for Research on Nicotine & Tobacco (SRNT-E) Conference to be held virtually September 15-17, 2021. Presentation Details "Cytisinicline may benefit smokers who previously failed to quit smoking with varenicline: A subgroup analysis of the ORCA-1 trial" A subgroup analysis from the ORCA-1 Phase 2 study of smokers who had previously failed Chantix® (varenicline) demonstrated a Week 4 abstinence rate of 51.3% upon treatment with cytisinicline using the three times daily (TID) regimen, compared with 15.8% with placebo (p= 0.009).
- 09/14/2021
|
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics. "We are excited to welcome our new clinical team members to Achieve and look forward to their contributions to the cytisinicline development program, including their efforts to support our fully enrolled Phase 3 ORCA-2 trial in combustible cigarette cessation and the planned Phase 2 ORCA-V1 trial in nicotine e-cigarette cessation," commented Dr. Cindy Jacobs, Achieve's President and Chief Medical Officer.
- 08/13/2021
|
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript
- Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript
- 08/13/2021
|
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Events & Highlights Announced completion of enrollment in the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3.0 mg cytisinicline dosed 3 times daily (TID) compared to placebo in adult smokers Awarded grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) for the evaluation of cytisinicline in cessation of nicotine e-cigarette use Issued two new patents from the United States Patent and Trademark Office covering the novel 3.0 mg TID cytisinicline dosing regimen Closed financing with gross proceeds of $23 million, prior to deducting underwriting discounts and offering expenses "In the second quarter, we continued to demonstrate our commitment to stakeholders by delivering on key milestones that advance our clinical program, and ultimately, cytisinicline's potential ability to help millions of people who struggle with nicotine addiction to live healthier lives," commented John Bencich, Chief Executive Officer of Achieve.
- 08/11/2021
|
Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,083,715 and U.S. Patent No.
- 08/11/2021
|
Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its second quarter 2021 financial results and provide an update on the cytisinicline development program on Thursday, August 12, 2021 at 4:30PM EDT. To access the webcast, log on to the Investor Relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts.
- 08/03/2021
|
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. This initial grant award, to commence on August 1, 2021, will be utilized to complete critical regulatory and clinical operational activities, such as protocol finalization, clinical trial site identification, and submission of a new IND to FDA for investigating cytisinicline in nicotine e-cigarette users.
- 07/22/2021
|
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
- ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / June 29, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Phase 3 ORCA-2 trial of cytisinicline has reached its enrollment target of 750 adult smokers. The ORCA-2 trial sites are no longer enrolling new subjects, however those currently in screening will be allowed to participate provided they meet entry criteria.
- 06/29/2021
|
Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / June 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 16/993,522 (the ‘522 Application) and U.S. Patent Application No.
- 06/03/2021
|
Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conference
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / June 2, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the company will be participating in the LD Micro Invitational XI Conference, being held virtually from June 8-10, 2021. John Bencich, Chief Executive Officer, is scheduled to host a virtual presentation on Wednesday, June 9, 2021, at 2:30 p.m.
- 06/02/2021
|
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 27, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of its underwritten public offering of 3,285,714 shares of its common stock at a public offering price of $7.00 per share, which includes 428,571 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $23.0 million.
- 05/27/2021
|
Achieve Life Sciences Stock Plunges After Raising $20M Via Equity at 19% Discount
- Achieve Life Sciences Inc (NASDAQ: ACHV) has priced its underwritten public offering of 2.9 million at $7 per share, representing a discount of 19% from the last close price of $8.61. Underwriters have a 30-day option to purchase up to an additional 428 thousand shares.
- 05/25/2021
|
Achieve Life Sciences Announces Proposed Underwritten Public Offering
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 24, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock. In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
- 05/24/2021
|
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2021 Results - Earnings Call Transcript
- Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Events & Highlights Provided update on the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3.0 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 17 clinical sites in the United States Published Phase 2b ORCA-1 safety, efficacy, and compliance results in Nicotine and Tobacco Research Announced the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Achieve's Board of Directors Published RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) in Addiction "In the first quarter, we've seen great interest and increased momentum in the ORCA-2 trial and look forward to completing enrollment by the middle of the year," commented John Bencich, Chief Executive Officer of Achieve.
- 05/13/2021
|
Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its first quarter 2021 financial results and provide an update on the cytisinicline development program on Thursday, May 13, 2021 at 4:30PM EDT. To access the webcast, log on to the Investor Relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts.
- 05/04/2021
|
Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research
- Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced publication of the results from the Phase 2b ORCA-1 trial in the scientific journal Nicotine and Tobacco Research. ORCA-1 evaluated the efficacy and safety of cytisinicline across various dosing and administration schedules in 254 smokers in the United States.
- 04/14/2021
|
Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) (varenicline) in Addiction
- Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 25, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced online publication of the results from the Phase 3 RAUORA trial in the scientific journal Addiction. The RAUORA study was led by Dr. Natalie Walker, Associate Professor at the University of Auckland, and evaluated the effectiveness and safety of cytisinicline compared to varenicline (Chantix®) as a smoking cessation aid in 679 indigenous New Zealanders (Māori) or their extended family.
- 03/25/2021
|
Achieve Life Sciences to Participate in M-Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
- Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 16, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Achieve's Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M-Vest and Maxim Group. The conference will take place on March 17 to 19 from 9:00 am-5:00 pm EDT featuring roundtable discussions, issuer presentations, fireside chats, and live Q&A with company CEOs moderated by Maxim Research Analysts.
- 03/16/2021
|
Achieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to the company's Board of Directors, effective immediately. "We are excited to welcome Dr. Martell and Dr. Jacobs to the board", commented Rick Stewart, Achieve's Executive Chairman of the Board of Directors.
- 03/15/2021
|
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2020 Results - Earnings Call Transcript
- Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2020 Results - Earnings Call Transcript
- 03/11/2021
|
Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program. Recent Events & Highlights Initiated the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the United States Presented data on smoker and e-cigarette user attitudes and perceptions on quitting at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting on February 24, 2021 Closed financing of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses, in December 2020 Facilitated Smoking Cessation Key Opinion Leader Virtual Roundtable in November 2020 "We concluded 2020 in the best financial position since the Company's inception and with the Phase 3 ORCA-2 trial underway at 15 well-established smoking cessation research centers in the United States.
- 03/11/2021
|
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call and Webcast on March 11, 2021
- SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 4, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its fourth quarter and year-end 2020 financial results and provide an update on the cytisinicline development program on Thursday, March 11, 2021 at 4:30 PM ET. To access the webcast, log on to the Investor Relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts.
- 03/04/2021
|
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
- SEATTLE and VANCOUVER, B.C., Dec. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the...
- 12/07/2020
|
Achieve Life Sciences Announces Pricing of $15 Million Public Offering
- SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the...
- 12/03/2020
|
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q3 2020 Results - Earnings Call Transcript
- Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q3 2020 Results - Earnings Call Transcript
- 11/13/2020
|
Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
- SEATTLE and VANCOUVER, BC, Oct. 29, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it...
- 10/29/2020
|
Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020
- SEATTLE and VANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company...
- 10/27/2020
|
Pharma Companies Have Improved How They Engage with Healthcare Providers During COVID-19, Finds New Research from Accenture
- Pharma companies have improved how they engage with healthcare providers during COVID-19, says Accenture.
- 08/10/2020
|
Brenntag AG (BNTGF) CEO Christian Kohlpaintne on Q2 2020 Results - Earnings Call Transcript
- Brenntag AG. (OTCPK:BNTGF) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Christian Kohlpaintne - Chief Executive Officer Georg Müller - Chief Financial Officer Conference Call Participants Rory McKenzie - UBS Laurent Favre - Exane BNP Paribas Rajesh Kumar - HSBC Markus Mayer - Baader Helvea Steven Goulden - Deutsche Bank Isha Sharma - MainFirst Bank Chetan Udeshi - JPMorgan.
- 08/09/2020
|
Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q2 2020 Results - Earnings Call Transcript
- Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Jaime Xinos - Executive Vice President of Commercial Richard Stewart - Chief Executive Officer Cindy Jacobs - Executive Vice President & Chief Medical Officer John Bencich - Chief Financial Officer & Chief Operating Officer Conference Call Participants Michael Higgins - Ladenburg Thalmann John Vandermosten - Zacks Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the Achieve Life Sciences Second Quarter 2020 Earnings Conference Call.
- 08/09/2020
|
HighRadius Adds New Leader to Drive Finance Digital Transformation in Growing Enterprise Client Base
- HighRadius, a fintech enterprise Software-as-a-Service (SaaS) company specializing in automating the order-to-cash and treasury management processes,
- 08/07/2020
|
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2020 financial results and provided an update on the cytisinicline clinical development program.
- 08/06/2020
|
Penn State Microbiome Center and GALT Enter Collaboration to Advance Research
- Researchers will utilize GALT's Prospector high-throughput microbial isolation and cultivation system to generate banks of live microbial isolates.
- 08/06/2020
|
Achieve Life Sciences (ACHV) Set to Announce Quarterly Earnings on Thursday
- Achieve Life Sciences (NASDAQ:ACHV) is set to post its quarterly earnings results after the market closes on Thursday, August 6th. Analysts expect Achieve Life Sciences to post earnings of ($0.19) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Achieve Life Sciences (NASDAQ:ACHV) […]
- 08/05/2020
|
STERIS plc (STE) CEO Walter Rosebrough on Q1 2021 Results - Earnings Call Transcript
- STERIS plc (NYSE:STE) Q1 2021 Results Conference Call August 03, 2020 10:00 AM ET Company Participants Julie Winter - Investor Relations Walter Rosebrough - President and Chief Executive Officer Michael Tokich - Senior Vice President and Chief Financial Officer Daniel Carestio - Senior Vice President and Chief Operating Officer Conference Call Participants David Turkaly - JMP Securities Christopher Cooley - Stephens Inc Michael Matson - Needham and Company Lawrence Keusch - Raymond James Matthew Mishan - KeyBanc Capital Markets Presentation Operator Good day, and welcome to the STERIS PLC First Quarter Fiscal 2021 Conference Call and Webcast.
- 08/04/2020
|
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
- QIAGEN reports full results for second quarter and first half of 2020
- 08/04/2020
|
Samyang Biopharm USA Announces Hyun Jung Helen Lee, M.D., Named to PharmaVOICE 100
- Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Biopharmaceuticals Corp. (https://samyangbiopha
- 08/03/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Craving Healthcare: A Beginner's Guide And My 7 Picks
- The Healthcare sector has significantly outperformed the S&P 500 in the last decade and with lower volatility – the only sector to do so.
- 07/31/2020
|
The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 30)
Achieve Life Sciences Inc (NASDAQ: ACHV)
Annexon Inc (NASDAQ: ANNX) (IPOed July 24)
Atossa Therapeutics...
- 07/31/2020
|
Ecolab : Second Quarter Reported Diluted Continuing Operations EPS $0.44; Adjusted Diluted Continuing Operations EPS $0.65, -49% | MarketScreener
|
AKKA: First-half 2020 Revenue
- Regulatory News: AKKA (Paris:AKA) (BSE:AKA) (ISIN:FR0004180537): H1 2020 performance Low point in activity reached in May Solid performance of Data Re
- 07/27/2020
|
QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher
- QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher
- 07/22/2020
|
Kronos Bio Appoints Barbara Kosacz, Chief Operating Officer and General Counsel
- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to trans
- 07/20/2020
|
Emerging Market and Legal Trends in the Top Five Global Startup Ecosystems
- The recently published Global Startup Ecosystem Report 2020 ranks the top global startup ecosystems by metrics including performance, funding, connectedness, talent, and knowledge to highlight the winning startup cities worldwide.
- 07/17/2020
|
Model N Announces Date of Third Quarter Fiscal Year 2020 Financial Results
- Model N, Inc. (NYSE: MODN), the leading provider of cloud revenue management solutions for Life Sciences and High Tech companies, plans to announce fi
- 07/14/2020
|
Qiagen N : provides update on Q2 2020 results, announces strong outlook for Q3 and FY 2020, and 2021 perspectives in light of coronavirus pandemic | MarketScreener
|
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020
- IGC announces its financial results for the Fiscal Year Ended March 31, 2020.
- 07/13/2020
|
New APM Study Reveals the Contribution of Projects and Project Management in the Health, Pharmaceutical and Life Sciences Sector
- Association for Project Management (APM), results of a study of the contribution of project management in the UK healthcare sector
- 07/07/2020
|
Salesforce.com: Moving Toward Good Health (NYSE:CRM)
- Salesforce.com has a significant presence in the healthcare segment and there are indications of continued strong momentum.
- 07/06/2020
|
Median Technologies Is Awarded the Euronext European Rising Tech Label
- Regulatory News: Median Technologies (Paris:AMLDT), The Imaging Phenomics Company® (ALMDT) announced today that it has been awarded the Euronext Europ
- 07/06/2020
|
Digital Microscopes Market to Surpass US$ 1,743.9 Million Globally by End Of 2027, Says CMI | | IT Business Net
- SEATTLE--(BUSINESS WIRE)--#DigitalMicroscopes--According to Coherent Market Insights, the global digital microscopes market is estimated to be valued at US$ 1,124.0 million in 2020, and is expected to
- 07/02/2020
|
MastOR Secures Seed Funding from Sofinnova Partners to Develop its Laparoscopy Assistance Platform | | IT Business Net
- PARIS, FRANCE / ACCESSWIRE / July 2, 2020 / MastOR, a medical device company developing a surgical robot for laparoscopy assistance, announced today a €3M equity round through a seed investment from t
- 07/02/2020
|
Sofinnova Partners : MastOR Secures Seed Funding from Sofinnova Partners to Develop its Laparoscopy Assistance Platform
|
Boom biotecnológico a la vista: Caixa Capital Risc, Inveready e Ysios anticipan un mayor apetito inversor y nuevas oportunidades
- La pandemia traerá un boom de inversión en biotecnología: los principales fondos españoles dan las claves para invertir en un sector muy especializado.
- 07/02/2020
|
Sofinnova Partners : Announces Two First Investments from its MD Start III Medtech Acceleration Fund
|
Sofinnova Partners Announces Two First Investments from its MD Start III Medtech Acceleration Fund
- Sofinnova Partners announces two first investments from its MD Start III Medtech Acceleration Fund
- 07/02/2020
|
HC2 Holdings Provides Update on Strategic Initiatives | MarketScreener
|
Agilent Technologies Inc (NYSE:A) Holdings Cut by Guggenheim Capital LLC
- Guggenheim Capital LLC cut its position in Agilent Technologies Inc (NYSE:A) by 31.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,478 shares of the medical research company’s stock after selling 23,802 shares during the quarter. Guggenheim Capital LLC’s holdings in Agilent Technologies […]
- 07/01/2020
|
Agilent Technologies (NYSE:A) Stock Rating Reaffirmed by Goldman Sachs Group
- Agilent Technologies (NYSE:A)‘s stock had its “neutral” rating reaffirmed by equities researchers at Goldman Sachs Group in a research report issued on Wednesday, Stock Target Advisor reports. Other equities research analysts have also recently issued research reports about the company. Cfra cut their target price on Agilent Technologies from $89.00 to $85.00 and set a […]
- 07/01/2020
|
Recent Analysts’ Ratings Changes for Chart Industries (GTLS)
- A number of research firms have changed their ratings and price targets for Chart Industries (NASDAQ: GTLS): 6/29/2020 – Chart Industries was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $62.00 price target on the stock. 6/24/2020 – Chart Industries was upgraded by analysts at […]
- 07/01/2020
|
ACHV: RAUORA: Cytisinicline’s Superior Side Effect Profile
- By John Vandermosten, CFA NASDAQ:ACHV On Monday, Achieve Life Sciences, Inc. (NASDAQ:ACHV) updated the investment community on the status of New Zealand’s RAUORA 1 study, which was expected to announce completion in the months leading up to the September SRNT conference. While full results were not provided, the study’s principal investigator did announce that cytisinicline was as good as
- 06/30/2020
|
Accenture (ACN) Receives a Hold from Wells Fargo - Markets
- Wells Fargo analyst Edward Caso maintained a Hold rating on Accenture (ACN – Research Report) on June 25. The company’s
- 06/30/2020
|
ÖAW nahm 96 neue Stipendiat/innen auf
- Stipendien in Höhe von insgesamt mehr als 10 Mio. Euro wurden an herausragende Nachwuchswissenschaftler/innen vergeben.
- 06/30/2020
|
All About the Berkeley Lights Stock IPO
- For some reason, IPOs are coming out of the woodwork these days. Seems strange when you consider that just three months ago, all hell was breaking loose, and everyone seems to have forgotten about that. In fact, since the first-ever mention of the Woohoo Flu, the Nasdaq has gone up by +13%. Maybe everyone's rushing to IPO before the door slams shut again? It was only several months ago that we wrote about 'How Berkeley Lights Enables Synthetic Biology,' and now they've filed for an IPO, which means we get to take a look under the hood. We'll assume you're
- 06/30/2020
|
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (NASDAQ: ACHV) and Intercept Pharma (NASDAQ: ICPT) - Markets
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Achieve Life Sciences (ACHV –
- 06/29/2020
|
Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 14,634,146 shares of common stock at a price of $0.41 per share in a registered direct offering, resulting in total gross proceeds of approximately $6 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about July 1, 2020, subject to customary closing conditions.
- 06/29/2020
|
Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking
- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the successful topline results from the New Zealand RAUORA Phase 3 non-inferiority clinical trial comparing cytisinicline to varenicline (Chantix®) in Māori (indigenous New Zealanders) and whānau (family) of Māori. The study was led by Dr. Natalie Walker, Associate Professor at the University of Auckland, and was funded by the Health Research Council of New Zealand.
- 06/29/2020
|
Seoul’s startup and tech ecosystem is world class — here’s what you need to know
- The city is already home to 8,708 startups, 85 accelerators, and the country has a total of 10 unicorns. And now, Seoul entered the top 20 startup ecosystems in the world.
- 06/29/2020
|
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
- Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentations
- 06/29/2020
|
Agilent Technologies Inc (NYSE:A) Shares Sold by Skandinaviska Enskilda Banken AB publ
- Skandinaviska Enskilda Banken AB publ reduced its position in Agilent Technologies Inc (NYSE:A) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 74,672 shares of the medical research company’s stock after selling 1,096 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s […]
- 06/28/2020
|
Agilent Technologies Inc (NYSE:A) Declares $0.18 Quarterly Dividend
- Agilent Technologies Inc (NYSE:A) declared a quarterly dividend on Wednesday, May 20th, Zacks reports. Investors of record on Tuesday, June 30th will be paid a dividend of 0.18 per share by the medical research company on Wednesday, July 22nd. This represents a $0.72 dividend on an annualized basis and a yield of 0.84%. The ex-dividend […]
- 06/28/2020
|
Liverpool hit harder than most by coronavirus but city has hope
- SPECIAL REPORT: We take an in-depth look at how the city plans to recover from the crisis and transform its position in the country
- 06/28/2020
|
Movers And Shakers Of The Week [June 22-27]
- We bring to you the latest edition of movers and shakers of the week in the Indian startup ecosystem.
- 06/27/2020
|
Accenture : Third Quarter Fiscal 2020 Transcript | MarketScreener
|
Gut health and exercise: studies suggest exercise could change microbiome
- Mounting evidence suggests that exercise can modify the types of bacteria that reside within our guts
- 06/26/2020
|
Global Respiratory Syncytial Virus Diagnostics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Becton, Dickinson and Co. | Technavio
- The Global Respiratory Syncytial Virus (RSV) Diagnostics Market will grow by $ 585.17 million during 2020-2024
- 06/26/2020
|
Hutchison China MediTech : Chi-Med Announces US$100 Million Equity Investment by General Atlantic | MarketScreener
|
Chi-Med Announces US$100 Million Equity Investment by General Atlantic
- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE...
- 06/25/2020
|
The Challenges And Opportunities For Life Sciences Industry - ValueWalk
- The life sciences industry, comprised largely of small and middle market companies, is the focus of a new report from the NCMM.
- 06/24/2020
|
Cantel Medical Corp. (NYSE: CMD) Q3 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of Cantel Medical Corp. - CMD stock
- 06/24/2020
|
Wave Life Sciences Ltd (NASDAQ:WVE) Sees Large Drop in Short Interest
- Wave Life Sciences Ltd (NASDAQ:WVE) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 4,690,000 shares, a drop of 5.8% from the May 31st total of 4,980,000 shares. Based on an average trading volume of 571,400 shares, the days-to-cover ratio […]
- 06/24/2020
|
IDC Reports Worldwide Blockchain Spending to Slow Down to US$ 4.3 Billion in 2020 - Fintech Singapore
- According to the April update of the IDC Worldwide Blockchain Spending Guide Worldwide and Asia/Pacific* blockchain spend will decline in 2020 as compared to the pre-COVID-19 forecast scenario.
- 06/24/2020
|
Why Buy These 2 TSX Stocks for Your TFSA Portfolio Now?
- TFSA investors should consider buying these two TSX stocks now for capital appreciation and steady income.
- 06/23/2020
|
Cognizant collaborates with Alphabet-owned Verily to facilitate Covid-19 testing across US
- The program is in operation at over 140 testing sites across 13 states and has supported the US administration with 284,000 COVID-19 tests.
- 06/23/2020
|
Hyundai Motor, Kia Motors and LG Chem Launch Global Competition to Invest in EV and Battery Start-ups | MarketScreener
|
Preis für einen, der Blinde sehend macht - Blick
- Botond Roska, Direktor am Institut für Molekulare und Klinische Ophthalmologie Basel (IOB) und Professor an der medizinischen und der naturwissenschaftlichen Fakultät der Uni Basel, erhält den mit einer Million dotierten Körber-Preis für die Europäische Wissenschaft.
- 06/23/2020
|
Steris PLC (NYSE:STE) Short Interest Update
- Steris PLC (NYSE:STE) was the target of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 1,360,000 shares, an increase of 7.1% from the May 31st total of 1,270,000 shares. Based on an average trading volume of 736,000 shares, the short-interest ratio is presently […]
- 06/23/2020
|
RWS Holdings plc (RWS) to Issue Dividend of GBX 1.75 on July 17th
- RWS Holdings plc (LON:RWS) announced a dividend on Tuesday, June 9th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, June 25th will be paid a dividend of GBX 1.75 ($0.02) per share on Friday, July 17th. This represents a yield of 0.29%. The ex-dividend date is Thursday, June 25th. The official announcement can be seen at […]
- 06/23/2020
|
Danaher Co. (NYSE:DHR) Plans Quarterly Dividend of $0.18
- Danaher Co. (NYSE:DHR) announced a quarterly dividend on Tuesday, May 5th, RTT News reports. Stockholders of record on Friday, June 26th will be given a dividend of 0.18 per share by the conglomerate on Friday, July 31st. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date […]
- 06/23/2020
|
Grant Thornton names Lisa Walkush to lead firmwide Industry program
- Grant Thornton LLP has named Lisa Walkush as its national managing principal of its Industry program, effective immediately. She will also serve on th
- 06/23/2020
|
LEG, H.I.G. Purchase 1.2M-SF Pharma Campus Outside Princeton
- One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
- 06/22/2020
|
Research reveals search engine habits of patients and HCPs -
- New research by Life Sciences by Stickyeyes, conducted for pharmaphorum, sheds light on people’s behaviour when searching for oncology information online.
- 06/22/2020
|
Das Kriegsende brachte den tiefsten Einschnitt der Firmengeschichte
(FOTO)
- SCHOTT erinnert an den legendären "Zug der 41 Glasmacher" vor 75 Jahren
- 06/22/2020
|
9,020 Shares in Steris PLC (NYSE:STE) Acquired by CIBC World Markets Inc.
- CIBC World Markets Inc. purchased a new position in shares of Steris PLC (NYSE:STE) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 9,020 shares of the medical equipment provider’s stock, valued at approximately $1,263,000. A number of other hedge funds and other institutional investors have […]
- 06/22/2020
|
Global Silicon Photonics Market (2019 to 2025) - Growing Deployment of 5G Networks Presents Opportunities - ResearchAndMarkets.com
|
Will the launch of Favipiravir mark the turnaround for Glenmark Pharma?
- If the drug proves to be efficacious for Covid treatment, Glenmark will cash in on first mover advantage.
- 06/21/2020
|
Zacks: Brokerages Expect Agilent Technologies Inc (NYSE:A) Will Post Earnings of $0.63 Per Share
- Brokerages predict that Agilent Technologies Inc (NYSE:A) will report $0.65 earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have provided estimates for Agilent Technologies’ earnings, with estimates ranging from $0.49 to $0.73. Agilent Technologies reported earnings of $0.76 per share during the same quarter last year, which would suggest a […]
- 06/20/2020
|
COVID-19 Impacts Demand on Ultraviolet (UV) Disinfection Equipment Market 2020-2024 | Evolving Opportunities With Advanced UV Inc. and American Ultraviolet Inc. | Technavio
|
COVID-19 Impacts Demand on Ultraviolet (UV) Disinfection Equipment Market 2020-2024 | Evolving Opportunities With Advanced UV Inc. and American Ultraviolet Inc. | Technavio
- The Global Ultraviolet (UV) Disinfection Equipment Market will grow by USD 2.06 bn during 2020-2024
- 06/20/2020
|
Croda International (LON:CRDA) Stock Price Passes Above 200-Day Moving Average of $4,852.05
- Croda International Plc (LON:CRDA) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4,852.05 and traded as high as $5,184.00. Croda International shares last traded at $5,158.00, with a volume of 229,431 shares traded. CRDA has been the topic of several recent research reports. JPMorgan […]
- 06/19/2020
|
Wave Life Sciences (NASDAQ:WVE) Stock Rating Upgraded by BidaskClub
- Wave Life Sciences (NASDAQ:WVE) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, BidAskClub reports. WVE has been the topic of several other reports. Mizuho reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Wave Life Sciences in a research note […]
- 06/19/2020
|
Apprentice.io Raises $7.5M in Funding | FinSMEs
- Apprentice.io, a Jersey City, NY-based provider of an intelligent software platform for Life Sciences manufacturing, raised $7.5m in funding
- 06/18/2020
|
Iowa Soybean Research Center has new partner
- Merschman Seeds joins advisory council of soybean research program based at Iowa State University.
- 06/18/2020
|
Plants use odour camouflage tricks to 'hide in plain sight'
- Plants have an upper hand in the ecological battle against insects by using odour camouflage tricks to 'hide in plain sight' and avoid being eaten, scientists say.
- 06/18/2020
|
Cegedim : Health Data collabore avec IBM Watson Health pour fournir un accès aux données de vie réelle | Zone bourse
|
Why should you seek an international assignment? - Business Review
- A bit of history: The British Empire was the largest and most complex form of human organization in history, ruling over approximately one quarter of the
- 06/18/2020
|
Calypso Biotech schließt Herstellung von CALY-002-Chargen für die
klinische Entwicklung ab
- AGC Biologics stellt auf IL-15 ausgerichteten humanisierten monoklonalen Antikörper her
- 06/18/2020
|
Oracle : Unveils Clinical One Data Collection Cloud Service | MarketScreener
|
Scientists as heroes: Let's keep that image in the public eye - STAT
- Their work on Covid-19 is bringing scientists the public acclaim they deserve. Prizes for scientific work can help keep them in the spotlight.
- 06/18/2020
|
Danaher (NYSE:DHR) Stock Rating Upgraded by Wolfe Research
- Danaher (NYSE:DHR) was upgraded by research analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage currently has a $195.00 price objective on the conglomerate’s stock. Wolfe Research’s price target suggests a potential upside of 10.59% from the company’s current […]
- 06/18/2020
|
RWS (LON:RWS) Shares Cross Above Two Hundred Day Moving Average of $576.16
- RWS Holdings plc (LON:RWS) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $576.16 and traded as high as $589.00. RWS shares last traded at $578.00, with a volume of 122,245 shares changing hands. A number of brokerages have weighed in […]
- 06/18/2020
|
Cegedim Health Data collabore avec IBM Watson Health pour fournir un accès aux données de vie réelle
- 16 juin 2020 - Cegedim Health Data annonce une collaboration avec IBM Watson Health pour l’intégration des données cliniques de vie réelle THIN®, The...
- 06/18/2020
|
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
- Press Release Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology. The Series A financing was led by Frazier Healthcare...
- 06/17/2020
|
Alliancebernstein L.P. Sells 3,265 Shares of Steris PLC (NYSE:STE)
- Alliancebernstein L.P. trimmed its stake in Steris PLC (NYSE:STE) by 2.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 136,177 shares of the medical equipment provider’s stock after selling 3,265 shares during the period. Alliancebernstein L.P. owned 0.16% of Steris […]
- 06/17/2020
|
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
- Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treat
- 06/17/2020
|
Führende Pharma-Verpackungsunternehmen verpflichten sich zu
Lieferungen für den Kampf gegen COVID-19
- Stevanato Group, SCHOTT und Gerresheimer bestätigen ihre Bereitschaft, den zukünftigen COVID-19-Impfstoff mit pharmazeutischen Glasbehältern zu unterstützen
- 06/16/2020
|
The Power of Dell Technologies On Demand for PowerScale | Direct2DellEMC
- Today we announced Dell EMC PowerScale. This new family of storage systems engineered with industry-leading storage software and server hardware is a new
- 06/16/2020
|
CognitOps Raises $3M in Seed Funding | FinSMEs
- CognitOps, an Austin, Texas-based AI startup whose software models automates warehouse management, completed its seed round of $3m
- 06/16/2020
|
CEGEDIM HEALTH DATA TO COLLABORATE WITH IBM WATSON HEALTH TO PROVIDE INTEGRATED ACCESS TO REAL-WORLD DATA
- Cegedim Health Data is collaborating with IBM Watson Health to integrate clinical rich real-world data into their real-world evidence solution portfolio.
- 06/16/2020
|
CognitOps Raises $3M Seed Funding Led by Chicago Ventures, and Appoints Roger Counihan Chief Revenue Officer
- CognitOps, an AI startup whose software models and automates warehouse management, announced today that it has completed its seed round of $3 million.
- 06/16/2020
|
CB2 Insights : Announces Delay in Filing Annual Financial Statements | MarketScreener
|
STERIS Plc.: Positive Long-Term Outlook Supports Dividend Growth Profile (NYSE:STE)
- Steris reported a record fiscal year for earnings supported by its leadership position in sterilization products and services. The company expects some near-ter
- 06/15/2020
|
ALS Ltd (ASX:ALQ) Insider Buys A$53,801.00 in Stock
- ALS Ltd (ASX:ALQ) insider Leslie Desjardins purchased 7,300 shares of the stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of A$7.37 ($5.23) per share, for a total transaction of A$53,801.00 ($38,156.74). Shares of ASX:ALQ opened at A$6.37 ($4.52) on Monday. ALS Ltd has a 12 month low […]
- 06/15/2020
|
Peel Hunt Boosts Gooch & Housego (LON:GHH) Price Target to GBX 1,200
- Gooch & Housego (LON:GHH) had its target price boosted by Peel Hunt from GBX 1,100 ($14.00) to GBX 1,200 ($15.27) in a research report sent to investors on Thursday, Stock Target Advisor reports. The firm currently has a buy rating on the stock. Separately, FinnCap restated a corporate rating on shares of Gooch & Housego […]
- 06/15/2020
|
Short Interest in Steris PLC (NYSE:STE) Grows By 7.1%
- Steris PLC (NYSE:STE) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totalling 1,360,000 shares, an increase of 7.1% from the May 14th total of 1,270,000 shares. Approximately 1.6% of the company’s stock are sold short. Based on an average daily […]
- 06/15/2020
|
Epsilen Bio appoints Julia Berretta as Chief Executive Officer and Mathieu Simon as Chairman of the Board
- Epsilen Bio appoints Julia Berretta as Chief Executive Officer and Mathieu Simon as Chairman of the Board.
- 06/15/2020
|
AVISO: Wissenschaft und Politik im Gespräch zu COVID-19 - Lehren für
die Zukunft
- Pressegespräch mit Nationalratspräsident Sobotka, ÖAW-Präsident Zeilinger und WissenschaftlerInnen
- 06/12/2020
|
HC2 Holdings Announces Executive Management Change
- HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE: HCHC), a diversified holding company, announced today its Board of Directors has appointed Wayne Barr, Jr. as
- 06/11/2020
|
Repligen: Management Gambled With 2020 Guidance But Long-Term Growth Story Looks Compelling (NASDAQ:RGEN)
- Repligen develops and sells bioprocessing technologies and systems involved in the manufacturing of biological drugs. The company operates within a high growth,
- 06/10/2020
|
ÖAW startet Wettbewerb: Neue Comics zum Abenteuer Forschung gesucht
- Die Comics richten sich an 7- bis 10-jährige Kids. Die besten Wettbewerbsbeiträge werden mit 12.000 Euro prämiert.
- 06/10/2020
|
Becton, Dickinson And Company: A Market Leader Trading At A Reasonable Valuation (NYSE:BDX)
- Becton, Dickinson reported its fiscal Q2 earnings in May which beat expectations while noting significant disruptions amid the COVID-19 pandemic. A slowdown in
- 06/10/2020
|
IBM (NYSE:IBM) Rating Increased to Hold at Zacks Investment Research
- IBM (NYSE:IBM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports. The brokerage presently has a $140.00 target price on the technology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 6.17% from the stock’s current price. According […]
- 06/10/2020
|
RWS (LON:RWS) Price Target Lowered to GBX 610 at Barclays
- RWS (LON:RWS) had its price target decreased by investment analysts at Barclays from GBX 630 ($8.02) to GBX 610 ($7.76) in a research report issued on Wednesday, ThisIsMoney.Co.Uk reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 0.83% from the company’s previous close. RWS […]
- 06/10/2020
|
'It's a dangerous time to go dark': Advertisers prepare for an uncertain summer - Digiday
- No marketer would ever say they don’t care about cost savings, but the ability to pause and shift their spending matters more now that lockdowns are being eased.
- 06/10/2020
|
Data Center Firm DataBridge Sites Expands into Philadelphia, Maryland, and Chicago
- Three proven multi-tenant data centers have been brought together as a single-service entity by DataBridge Sites, offering cloud, colocation, and inte
- 06/10/2020
|
Phreesia, Inc. (PHR) CEO Chaim Indig on Q1 2021 Results - Earnings Call Transcript
- Phreesia, Inc. (NYSE:PHR) Q1 2021 Earnings Conference Call June 09, 2020 08:30 A.M. ET Company Participants Balaji Gandhi - VP, IR Chaim Indig - CEO Thomas Alti
- 06/09/2020
|
Zcube: Digital Health, Open Accelerator Is Seeking Innovators to Shape the Future of Health
- Zcube has launched the fourth edition of Open Accelerator, the international acceleration programme dedicated to startups in Life Sciences
- 06/09/2020
|
NeoGenomics: Buy And Hold This Specialist Biotech - The Gains Are Coming (NASDAQ:NEO)
- NeoGenomics runs a network of cancer-testing laboratories across the US, Switzerland and Singapore. The company offers a unique combination of services and prod
- 06/08/2020
|
Eyeing for higher education, list of scholarships for postgraduate courses
- Finance is no longer a concern, check out the list of scholarships for students to pursue postgraduate courses across India
- 06/07/2020
|
Australian share market shooting out the lights near 6000 points as dollar hits US70c - weekly review
- The Australian market got a full flush of excellent readings on the last day of trading before the long weekend.
- 06/05/2020
|
Hedge Funds Nibbling On Achieve Life Sciences, Inc. (ACHV)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/05/2020
|
Rückkehr an den Arbeitsplatz kann bisherige Belastungssituation verschärfen
- Durch die Corona-Krise fand sich im März beinahe die Hälfte der österreichischen ArbeitnehmerInnen unfreiwillig im Homeoffice wieder.
- 06/05/2020
|
DocuSign, Inc. (DOCU) CEO Dan Springer on Q1 2021 Results - Earnings Call Transcript
- DocuSign, Inc. (NASDAQ:DOCU) Q1 2021 Earnings Conference Call June 4, 2021 4:30 P.M. ET Company Participants Anne Leschin - Head of Investor Relations Dan Sprin
- 06/05/2020
|
Small Business Hiring Shows Second Month of Historic Decline
- The CBIZ Small Business Employment Index (“SBEI”) reported its second-largest decline in small business hiring, with its May reading showing a seasona
- 06/05/2020
|
Refinitiv Launches New Version of Matching for Ukrainian FX Traders | Finance Magnates
- Refinitiv today announced that it has launched a new version of Refinitiv Matching for Foreign Exchange (FX) traders specifically designed for Ukraine.
- 06/04/2020
|
Coronavirus latest: Experts call for Minister for Pandemics to see off other health crises
- A Minister for Pandemics must be appointed to see off the threat of future outbreaks, experts say. The government should also work to join up the arms of the health service and hold annual "war game" preparations to ensure we are ready for the latest biological threats.
- 06/04/2020
|
COVID-19’s Impact on Early Stage Venture Capital
- This may actually be one of the best times in history to raise early-stage capital.
- 06/04/2020
|
Impression Healthcare to focus exclusively on cannabinoid sales and drug development
- Medical cannabis company Impression Healthcare (ASX: IHL) has announced it will discontinue sales of its oral devices by the end of the month to focus its resources exclusively on cannabinoid sales and development activities.
- 06/03/2020
|
Global Managed Network Services Market Analysis and Forecasts to 2025 - ResearchAndMarkets.com
|
Accelerating pharma's digital IQ as customer engagement evolves -
- COVID-19 has brought many changes to the pharmaceutical industry, among them a need to change pharma company customer engagement and transform approaches to digital channels
- 06/02/2020
|
Kanton Zug unterstützt zukunftsfähige Startups mit 5 Millionen Franken | Fintech Schweiz Digital Finance News - FintechNewsCH
- Kanton Zug Startups mit fünf Millionen Franken. Der Regierungsrat hat sich dazu entschlossen, zukunftsfähige Startups zu unterstützen, die durch die Corona-Pandemie in ihrer Existenz bedroht sind.
- 06/02/2020
|
Gamification Market to Reach USD 37.00 Billion by 2027; Inclination towards Gamification Solutions for Promotional Purposes Will Facilitate Business, States Fortune Business Insights(TM)
- PUNE, India, Jun 01, 2020 (PR Newswire Europe via COMTEX) --
Key Companies Covered in Gamification Market Research Report are Microsoft Corporation, MPS...
- 06/01/2020
|
Illumina: Smart Products And Business - If You Know, You Know (NASDAQ:ILMN)
- After suffering an alarming dip in March on COVID-19 fears Illumina has bounced back, gaining 77% to trade at $363 at time of writing. Illumina has an estimated
- 06/01/2020
|
People & Places
- National The Hanover Insurance Group has appointed James A. Kelley as president of Hanover Specialty Industrial Property. Kelley is responsible for the
- 06/01/2020
|
ACHV: When Quitting Gets You to the Finish Line
- By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT First Quarter 2020 Review Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported first quarter results in an early morning press release and conference call held on May 14th 2020. The company concurrently filed its 2019 10-Q with the SEC. While disruptions related to the coronavirus have required new safety measures, Achieve now
- 05/29/2020
|
Veeva Systems Inc (NYSE: VEEV) Q1 2021 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of Veeva Systems Inc - VEEV stock
- 05/29/2020
|
Virtusa to Increase Speed, Reduce Costs of Critical Digital Transformation Initiatives
- Virtusa Corporation (NASDAQ GS: VRTU), a global provider of digital strategy, digital engineering, and IT services and solutions that help Global 2000 clients
- 05/28/2020
|
Doris Schmidauer übernimmt Ehrenschutz für Initiative „Reden Sie mit! Was macht Corona mit unserer psychischen Gesundheit?“
- Österreichs First Lady Doris Schmidauer unterstützt die Initiative der Ludwig Boltzmann Gesellschaft zu psychischer Gesundheit unter COVID-19 und ruft die österreichische Bevölkerung zur aktiven …
- 05/27/2020
|
Global Failure Analysis Market by Equipment, Technology, Application and Geography - Forecast to 2025 - ResearchAndMarkets.com
|
The 4 traits to look for when hiring a Customer Experience Manager - Business Review
- No matter the industry nor the type of the company, in our current highly competitive and in recession markets, customer experience strategies make the
- 05/25/2020
|
Corona-Pandemie verändert Arbeitsalltag der Menschen
- „Reden Sie mit!“-Initiative der Ludwig Boltzmann Gesellschaft zu Auswirkungen der Corona-Pandemie auf die psychische Gesundheit der Bevölkerung startet mit dem Thema Arbeit.
- 05/25/2020
|
Personalvermittler Randstad warnt vor Pauschalierungen
|
Model N Prices Offering of $150.0 Million of 2.625% Convertible Senior Notes Due 2025
- Model N, Inc. (NYSE: MODN), a leading provider of cloud revenue management solutions for Life Sciences and High Tech companies, announced today the pr
- 05/20/2020
|
Astrid Kleber ist neue Leiterin der Öffentlichkeitsarbeit und Kommunikation an der Universität für Bodenkultur Wien
- Mit Anfang Mai hat Astrid Kleber die Leitung der Öffentlichkeitsarbeit und Kommunikation an der BOKU übernommen.
- 05/19/2020
|
SDL Announces Certified Integration of Translation Management with Veeva Vault RIM
- SDL (LSE: SDL), the intelligent language and content company, announces it has advanced its partnership level with Veeva Systems (“Veeva”), a leader i
- 05/19/2020
|
Aufarbeitung der Home-Learning-Erfahrungen in der Schule notwendig
- Mit 18. Mai geht es für den Großteil der SchülerInnen wieder zurück in die Schulklassen.
- 05/18/2020
|
STERIS' (STE) CEO Walt Rosebrough on Q4 2020 Results - Earnings Call Transcript
- STERIS plc (NYSE:STE) Q4 2020 Earnings Conference Call May 14, 2020 10:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice
- 05/14/2020
|
Function as a Service Market 2020: Global Analysis, Share, Trends, Application Analysis and Forecast To 2027
- May 14, 2020 (Heraldkeepers) --
New York, May 14, 2020: The report covers detailed competitive outlook including the market share and company profiles of the...
- 05/14/2020
|
Nvidia unveils monstrous A100 AI chip with 54 billion transistors and 5 petaflops of performance
- Nvidia unwrapped its Nvidia A100 artificial intelligence chip today, and CEO Jensen Huang called it the ultimate instrument for advancing AI.
- 05/14/2020
|
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
- Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
- 05/14/2020
|
Venture Capitalist, Entrepreneur and Investor Ron Bauer Looks at 6 Ways to Raise Startup Capital in a Time of Crisis - StartUp Mindset
- The ongoing coronavirus pandemic has had an immeasurable impact on the business landscape. However, amidst crisis lies an opportunity for those who are ready, willing, and prepared to seize it, which means that thousands of people who have been dreaming of launching their own business for years will have their chance now or in …
- 05/14/2020
|
Contec, Inc., Milliken Partner to Produce Sporicidin® Brand Disinfectant Qualified to Kill Coronavirus
- Leading manufacturers partner to produce Sporicidin® brand disinfectants amid high demand for antibacterial cleaning solutions.
- 05/14/2020
|
The AI Eye: AWS Makes Amazon Kendra Generally Available and Honeywell Announces AI-Powered ThermoRebellion Temperature Monitoring Solution
- May 13, 2020 (Investorideas.com via COMTEX) --
Point Roberts, WA and Vancouver, BC - May 13, 2020 (Investorideas.com Newswire) Investorideas.com...
- 05/13/2020
|
Infosys: Mixed Quarter But Central Buy Thesis Remains Firm
- During the quarter, revenue growth was strongly driven by digital business. Life Sciences vertical came in the strongest with 11.9% Y/Y revenue growth. There we
- 05/13/2020
|
Analysis on Impact of Covid-19- Global Respiratory Syncytial Virus Diagnostics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Becton, Dickinson and Co. | Technavio
- The respiratory syncytial virus (RSV) diagnostics is poised to grow by USD 585.17 mn during 2020-2024, according to Technavio
- 05/13/2020
|
